Philip C Mack
Overview
Explore the profile of Philip C Mack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
4185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack P, Hirsch F
Clin Lung Cancer
. 2023 May;
24(5):401-406.
PMID: 37208221
Lung cancer is responsible for 1.8 million annual deaths. Non-small cell lung cancers (NSCLC) represent 85% of lung cancer tumors. While surgery is an effective early-stage treatment, the majority of...
12.
de Miguel-Perez D, Russo A, Gunasekaran M, Buemi F, Hester L, Fan X, et al.
Cancer
. 2022 Dec;
129(4):521-530.
PMID: 36484171
Background: Immune-checkpoint inhibitors (ICIs) are an effective therapeutic strategy, improving the survival of patients with lung cancer compared with conventional treatments. However, novel predictive biomarkers are needed to stratify which...
13.
Woo X, Srivastava A, Mack P, Graber J, Sanderson B, Lloyd M, et al.
Cancer Res
. 2022 Sep;
82(22):4126-4138.
PMID: 36069866
Significance: Patient-derived xenografts of lung cancer retain key features observed in the originating patient tumors and show expected responses to treatment with standard-of-care agents, providing experimentally tractable and reproducible models...
14.
Malapelle U, Pisapia P, Pepe F, Russo G, Buono M, Russo A, et al.
Lung Cancer
. 2022 Aug;
172:53-64.
PMID: 35998482
Liquid biopsy has revolutionized the management of cancer patients. In particular, liquid biopsy-based testing has proven to be highly beneficial for identifying actionable cancer markers, especially when solid tissue biopsies...
15.
Chen J, Huynh J, Wu C, Yu A, Matsukuma K, Semrad T, et al.
Cancer Chemother Pharmacol
. 2022 Jul;
90(3):217-228.
PMID: 35907014
Purpose: Aurora Kinase A (AKA) inhibition with gemcitabine represents a potentially synergistic cancer treatment strategy via mitotic catastrophe. The feasibility, safety, and preliminary efficacy of alisertib (MLN8237), an oral AKA...
16.
Mack P, Hirsch F, Bunn P, Minna J
J Clin Oncol
. 2022 Jun;
40(33):3787-3789.
PMID: 35759731
No abstract available.
17.
Mack P, Miao J, Redman M, Moon J, Goldberg S, Herbst R, et al.
Clin Cancer Res
. 2022 Jun;
28(17):3752-3760.
PMID: 35713632
Purpose: Dynamic changes in circulating tumor DNA (ctDNA) are under investigation as an early indicator of treatment outcome. Experimental Design: Serial plasma ctDNA (baseline, 8 weeks, and at progression) was...
18.
de Miguel-Perez D, Russo A, Arrieta O, Ak M, Barron F, Gunasekaran M, et al.
J Exp Clin Cancer Res
. 2022 Jun;
41(1):186.
PMID: 35650597
Background: Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive...
19.
Mack P, Gomez J, Rodilla A, Carreno J, Hsu C, Rolfo C, et al.
Cancer Cell
. 2022 May;
40(6):575-577.
PMID: 35504289
No abstract available.
20.
Mack P, Klein M, Ayers K, Zhou X, Guin S, Fink M, et al.
Oncologist
. 2022 Mar;
27(6):476-486.
PMID: 35298662
Introduction: Historically, high rates of actionable driver mutations have been reported in never-smokers with lung adenocarcinoma (ADC). In the era of modern, comprehensive cancer mutation sequencing, this relationship necessitates a...